The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation

Endocrine Reviews

Volumn 20, Issue 4, 1999, Pages 501-534

  Pestell, Richard G ^a   Albanese, Chris ^a   Reutens, Anne T ^a   Segall, Jeffrey E ^a   Lee, Richard J ^a   Arnold, Andrew ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 HYDROXYELLIPTICINE; ACTIVIN; ANGIOTENSIN; CYCLIC AMP; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; EPIDERMAL GROWTH FACTOR; ESTROGEN; FLAVOPIRIDOL; FOLLITROPIN; GLUCOCORTICOID; NERVE GROWTH FACTOR; PARATHYROID HORMONE; PHORBOL 13 ACETATE 12 MYRISTATE; PLATELET DERIVED GROWTH FACTOR; RETINOIC ACID; RHODOPSIN; SOMATOMEDIN B; SOMATOMEDIN C; STAUROSPORINE; THYROTROPIN; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VITAMIN D;

ADRENAL TUMOR; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; GENE DELETION; HORMONAL REGULATION; HYPOPHYSIS TUMOR; OVARY CANCER; PARATHYROID ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TESTIS CANCER; THYROID CANCER; TRANSCRIPTION REGULATION;

EID: 0033304945     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.20.4.501     Document Type: Review

References (482)

1. Cancer cell cycles
2. Inhibitors of mammalian G1 cyclin-dependent kinases
3. G1 phase progression: Cycling on cue
4. Cell cycle checkpoints: Preventing an identity crisis
5. The retinoblastoma protein and cell cycle control
6. The cyclin D1/PRAD1 oncogene in human neoplasia
7. Cyclin D1 and the cyclin dependent kinase regulatory proteins in tumorigenesis and differentiation
8. Mutation of cell cycle regulators
9. Cyclin D and oncogenesis
10. Oncogenes and cell proliferation
11. Cyclin D1 is a nuclear protein required for cell cycle progression in G1
12. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts
13. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression
14. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system
15. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle
16. Cyclin D1 protein expression and function in human breast cancer
17. Cyclin D1 is required for S-phase traversai in bovine tracheal myocytes
18. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin dependent kinase-pRb-controlled G1 checkpoint
19. Cyclin D1 is dispensible for G1 control in retinoblastoma gene-deficient cells independently of Cdk4 activity
20. Isolation of Drosophila cyclin D, a protein expressed in the morphogenetic furrow before entry into S phase
21. Developmental modification of the Drosophila cell cycle
22. Molecular cloning and chromosomal mapping of DNA rearranged wth the parathyroid hormone gene in a parathyroid adenoma
23. A novel cyclin encoded by a bcl1-linked candidate oncogene
24. Human D-type cyclin
25. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
26. The PRAD1/Cyclin D1 proto-oncogene: Genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint
27. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic helix-loop-helix regulators
28. Alternate splicing produces a novel cyclin D1 transcript
29. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
30. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts
31. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types
32. Mammalian G1 cyclins
33. Cloning of a D-type cyclin from murine erythroleukemia cells
34. Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation
35. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by Cdk2 binding and cyclin phosphorylation
36. Activation of cyclin E/Cdk2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E
37. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D: Cdk4/6 complexes results in active pRb
38. G1 phase hypo-phosphorylation of the retinoblastoma protein: Targeting to specific transcription factors
39. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1
40. Cyclin E-induced S phase without activation of the pRb/E2F pathway
41. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition
42. Different roles for cyclins D1 and E in regulation of the G1-to-S transition
43. Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein
44. Expression of NPAT, a novel substrate of cyclin E-Cdk2, promotes S-phase entry
45. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B
46. Cyclin A is required at two points in the human cell-cycle
47. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system
48. Differential regulation of E2F trans-activation by cyclin/Cdk2 complexes
49. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
50. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase
51. Human cyclin F
52. Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression
53. p53-Independent cyclin G expression in a group of mature neurons and its enhanced expression during nerve regeneration
54. A brain-specific activator of cyclin-dependent kinase 5
55. p35 Is a neural specific regulatory subunit of cyclin-dependent kinase 5
56. Identification of functional domains in the neuronal Cdk5 activator
57. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures and adult lethality
58. Role of cyclins in neuronal differentiation of immortalized hippocampal cells
59. The decision to enter mitosis
60. How proteolysis drives the cell cycle
61. Mitosis in transition
62. Cyclins and cancer II: Cyclin D and Cdk inhibitors come of age
63. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
64. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16(INK4a) but not by the alternative reading frame protein p19(ARF)
65. The Ink4a tumor suppressor gene product, p19(Arf), interacts with DM2 and neutralizes MDM2's inhibition of p53
66. Role of the INK4a locus in tumor suppression and cell mortality
67. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
68. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
69. The alternative product from the human CdkN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
70. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
71. Tumor surveillance via the ARF-p53 pathway
72. WAF1, a potential mediator of p53 tumor suppression
73. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of the cyclin D-dependent kinases
74. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
75. p27, A novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
76. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
77. p57KIP2, A structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene
78. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP1 requires binding to proliferating cell nuclear antigen
79. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1)
80. New functional activities for the p21 family of Cdk inhibitors
81. The p21(Cip1) and p27(Kip1) Cdk 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
82. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA
83. Identification of binding domains on p21Cip1 cyclin-dependent kinase inhibitor
84. Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1
85. p21-Containing cyclin kinases exist in both active and inactive states
86. Inhibition of cyclin-dependent kinases by p21
87. Cyclin-binding motifs are essential for the function of p21(CIP1)
88. Cell-cycle inhibition by independent Cdk and PCNA binding domains in p21(Cip1)
89. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen
90. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme
91. Mice lacking p21(CIP1/WAF1) undergo normal development, but are defective in G1 checkpoint control
92. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with Cdk4 and Cdk2
93. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle
94. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (GO state) in fibroblasts
95. Regulation of cyclin E and p27Kip during mitosis in Balb/c3T3 cells
96. Differential modulation of G1 cyclins and the Cdk inhibitor p27(kip1) by platelet-derived growth factor and plasma factors in density-arrested fibroblasts
97. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes
98. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
99. p27(Kip1), A cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
100. Regulation of cyclin D-dependent kinase 4 (Cdk4) by Cdk4-activating kinase
101. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β
102. Formation of p27-Cdk complexes during the human mitotic cell cycle
103. Cyclin E-Cdk2 is a regulator of p27Kip1
104. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice
105. Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors
106. Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1
107. Rapamycin resistance tied to defective regulation of p27(Kip1)
108. Ablation of the Cdk inhibitor p57(Kip2) results in increased apoptosis and delayed differentiation during mouse development
109. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome
110. Increased and altered DNA binding of p53 by S and G2/M but not G1 cyclin-dependent kinases
111. B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation
112. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor
113. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors
114. Cdk-independent activation of estrogen receptor by cyclin D1
115. Cyclin D1 stimulation of estrogen receptor transcription independent of Cdk4 activation
116. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1
117. D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain
118. Sp-1 binds promoter elements regulated by the RB protein and Sp-1 mediated transcription is stimulated by RB coexpression
119. The retinoblastoma protein, more than a tumor suppressor
120. The retinoblastoma tumor suppressor protein
121. Regulation of transcription by proteins that control the cell cycle
122. Cdk-activating kinase complex is a component of human transcription factor TFIIH
123. Association of Cdk-activating kinase subunits with transcription factor TFIIH
124. Substrate specificity of the Cdk-activating kinase (CAK) is altered upon association with TFIIH
125. D-Type cyclin-dependent kinase activity in mammalian cells
126. Regulation of Cdk-activating kinase (CAK) is altered upon association with TFIIH
127. Identification of multiple cyclin subunits of human P-TEFb
128. Mitotic repression of RNA polymerase III transcription in vitro mediated by phosphorylation of TFIIIB component
129. Mitotic regulation of TFIID: Inhibition of activator-dependent transcription and changes in subcellular localization
130. Mechanistic analysis of RNA polymerase III regulation by the retinoblastoma protein
131. Displacement of sequence specific transcription factors from mitotic chromatin
132. Cell-cycle regulation of poly(A) polymerase by phosphorylation
133. Phosphorylation of the adenovirus E1A-associated 300 kDa protein in response to retinoic acid and E1A during the differentiation of F9 cells
134. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains
135. Nuclear receptor coactivators and corepressors
136. The transcriptional coactivators p300 and CBP are histone acetyltransferases
137. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
138. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
139. Involvement of the cell-cycle inhibitor Cip/Waf1 and the E1A-associated p300 in terminal differentiation
140. Regulation of NF-kB by cyclin-dependent kinases associated with the p300 coactivator
141. Recruitment of p300/CBP in p53-dependent signal pathways
142. Factors regulating macrophage production and growth. Purification and some properties of the colony stimulating factor from medium conditioned by mouse L cells
143. Colony stimulating factor-1 (macrophage colony stimulating factor)
144. CSF-1 signal transduction
145. CSF-1 signal transduction: What is of functional significance?
146. v-raf Confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation
147. Mitogenic signalling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression
148. Rescue of defective mitogenic signaling by D-type cyclins
149. Myc but not Fos rescue of PDGF signalling block caused by kinase inactive Src
150. Calcium as a regulator of the proliferation of normal, but not transformed, chicken fibroblasts in plasma-containing medium
151. Growth factors: Their role in the control of cell proliferation
152. Dual control of cell growth by somatomedins and platelet derived growth factor
153. G1 events and regulation of cell proliferation
154. Growth-regulated expression of D-type cyclin genes in human diploid fibloblasts
155. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27(KIP1)
156. Repression of p27(kip1) synthesis by platelet derived growth factor in BALB/c3T3 cells
157. Pituitary extracts and steroid hormones in the control of 3T3 cell growth
158. Association of fibroblast growth factor receptor-1 with c-src correlates with association between c-src and cortactin
159. Molecular mechanisms of angiogenesis-fibroblast growth factor signal transduction
160. 1 events
161. Positive and negative regulation of D-type cyclin expression in skeletal myoblasts by basic fibroblast growth factor and transforming growth factor β. A role for cyclin D1 in control of myoblast differentiation
162. Cyclin mediated inhibition of muscle gene expression via a mechanism that is independent of pRB phosphorylation
163. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase
164. Coupling of the cell cycle and myogenesis through the cyclin-dependent interaction of MyoD with Cdk4
165. Epidermal growth factor (EGF) is required only during the traverse of early G1 in PDGF stimulated density-arrested BALB/c-3T3 cells
166. Post transcriptional control of the onset of DNA synthesis by an insulin-like growth factor
167. 1 progression and protein modification by SmC/IGF I
168. Insulin-like growth factors and their binding proteins: Biological actions
169. Mice containing null mutations of the genes encoding insulin-like growth factor I (IGF-I) and type I IGF receptor (IGF-IR)
170. Role of insulin-like growth factors in embryonic and postnatal growth
171. Effect of null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts
172. The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen
173. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor
174. Molecular and cellular aspects of the insulin-like growth factor I receptor
175. Mechanisms of hormone action
176. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
177. Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP
178. Insulin-like growth factor-I induces cyclin D1 expression in MG63 human osteosarcoma cells in vitro
179. Reduced cyclin D1 expression in the cerebella of nutritionally deprived rats correlates with developmental delay and decreased cellular DNA synthesis
180. Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebellar development
181. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development
182. Cyclin D1 provides a link between development and oncogenesis in the retina and breast
183. Interleukin-2 mediated elimination of the p27(KIP1) cyclin-dependent kinase inhibitor prevented by rapamycin
184. Differential control of cyclins D1 and D3 and the Cdk inhibitor p27Kip1 by diverse signalling pathways in Swiss 3T3 cells
185. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research
186. The epidermal growth factor family
187. Transforming p21(ras) mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
188. Transforming growth factor-α enhances cyclin D1 transcription through the binding of early growth factor response protein to a cis-regulatory element in the cyclin D1 promoter
189. Coupling of epidermal growth factor (EGF) with the antiproliferative activity of cAMP induces neuronal differentiation
190. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts
191. Nerve growth factor: A tale of two receptors
192. Nerve growth factor activates a ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB
193. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway
194. Nerve growth factor regulates the expression and activity of p33(Cdk2) and p34(cdc2) kinases in PC12 pheochromocytoma cells
195. NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1
196. Nerve growth factor-induced accumulation of PC12 cells expressing cyclin D1: Evidence for a G1 phase block
197. Nerve growth factor induces transcription of the p21 WAF1/CIP1 and cyclin D1 genes in PC12 cells by activating the Sp1 transcription factor
198. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons
199. Cyclin D1 is an essential mediator of apoptotic neuronal cell death
200. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27(kip1), inhibits growth and enhances apoptosis
201. Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E
202. Cyclin D1 induced apoptosis maintains the integrity of the G1/S checkpoint following ionizing radiation irradiation
203. Cyclin D1 and p21/waf1 are both involved in p53 growth suppression
204. The Cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation
205. Down-regulation of cyclin F levels during nerve growth factor-induced differentiation of PC12 cells
206. The transforming growth factor-βs
207. Requirement of transforming growth factor-β (TGF-β) type II receptor for TGF-β-induced proliferation and growth inhibition
208. Indirect mitogenic effect of transforming growth factor-β on cell proliferation of subconjunctival fibroblasts
209. Connective tissue growth factor: A mediator of TGF-β action on fibroblasts
210. Transforming growth factor β and cell cycle regulation
211. Tumor suppressor activity of the TGFβ pathway in human cancers
212. Biology of TGFβ in knockout and transgenic mouse models
213. Regulation of cell cycle synchronization by decapentaplegic during Drosophila eye development
214. Intracellular signaling: The mad way to do it
215. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function
216. Receptor-associated Mad homologues synergize as effectors of the TGF-β response
217. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4
218. Human Smad3 and Smad4 are sequence-specific transcription activators
219. Transforming growth factor β1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with a G1/S-phase growth arrest
220. Cell cycle arrest in G0/G1 phase by contact inhibition and TGF-β 1 in mink Mv1Lu lung epithelial cells
221. TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest
222. Transforming growth factor β stabilizes p15INK4B protein, increases p15(INK4b)-Cdk4 complexes, and inhibits cyclin D1-Cdk4 association in human mammary epithelial cells
223. 1 arrest in a human melanoma cell line lacking p15(INK4b). Evidence for cooperation between p21(Cip1/WAF1) and p27(Kip1)
224. Repression of the Cdk activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the Cdk inhibitor p15
225. TGFβ-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein
226. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase
227. Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1
228. Pre-existent patterns in Xenopus pole cells revealed by induction with activin
229. Mesoderm-inducing factors in early development
230. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP
231. Activin A induction of cell-cycle arrest involves modulation of cyclin D2 and p21(CIP/WAF1) in plasmacytic cells
232. Mechanism of angiotensin II-induced proliferation in bovine adrenocortical cells
233. Angiotensin II stimulates growth and steroidogenesis in zona fasciculata/reticularis cells from bovine adrenal cortex via the AT1 receptor subtype
234. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers
235. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells
236. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro
237. Heterotrimeric G proteins: Organizers of transmembrane signals
238. Calcium signaling
239. Role of calcium in angiotensin II-mediated aldosterone secretion
240. Differential Raf requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters and calcium
241. Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor
242. cPLA2 Is phosphorylated and activated by MAP kinase
243. Calcium signaling in neurons: Molecular mechanisms and cellular consequences
244. Angiotensin II-induced protein phosphorylation in neonatal rat cardiac fibroblasts
245. Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-gamma 1 in vascular smooth muscle cells
246. Angiotensin II stimulates calcium dependent activation of c-Jun N-terminal kinase
247. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor
248. Angiotensin II (AII) activation of cyclin D1-dependent kinase activity
249. Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone
250. Calcium modulates the cyclin D1 expression in a rat parathyroid cell line
251. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors
252. Thyrotropin and dibutyryl cyclic AMP increase levels of c-myc and c-fos mRNAs in cultured rat thyroid cells
253. 3',5'-Cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line
254. Thyrotropin induces G1 cyclin expression and accelerates G1 phase after insulin-like growth factor I stimulation in FRTL-5 cells
255. The phosphatase inhibitor okadaic acid stimulates the TSH-induced G1-S phase transition in thyroid cells
256. A requirement for cyclin D3-cyclin-dependent kinase (Cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thyrocytes
257. Hormonal control of gene expression in the ovary
258. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
259. Hormone-induced proliferation and differentiation of granulosa cells: A coordinated balance of the cell cycle regulators cyclin D2 and p27(Kip1)
260. Growth factors in breast cancer
261. Oncogenes as clinical prognostic indicators
262. Steroids, growth factors and cell cycle controls in breast cancer
263. Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor
264. Estrogen receptor gene disruption: Molecular characterization and experimental and clinical phenotypes
265. Disruption of estrogen receptor gene prevents 17β-estradiol-induced angiogenesis in transgenic mice
266. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility
267. Gene regulation by steroid hormones
268. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors
269. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
270. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol
271. Steroid hormone regulation of nuclear proto-oncogenes
272. SNF2β-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells
273. Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3 and thyroid hormone receptors in mammalian cells
274. A possible involvement of TIF1 α and TIF1 β in the epigenetic control of transcription by nuclear receptors
275. Role of co-activators co-repressors in the mechanism of steroid/thyroid receptor action
276. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long term tissue culture
277. Oestrogen-responsive human breast cancer in long term tissue culture
278. Mode of estrogen action on cell proliferation in CAMA-1 cells. II. Sensitivity of G1 phase population
279. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells
280. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34Cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells
281. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation
282. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
283. Estrogen-dependent cyclin E-Cdk2 activation through p21 redistribution
284. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
285. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
286. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants
287. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
288. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
289. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex
290. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse
291. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
292. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus
293. 3H mouse and its control by ovarian hormones. An autoradiographic study
294. Endocrine and other influences in the normal development of the breast
295. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors. Mechanistic studies
296. Roles of estrogen and Progesterone in normal mammary gland development
297. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities
298. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes
299. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?
300. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21
301. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo
302. Cellular biology and biochemistry of the retinoids
303. The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificities of the DNA binding domains
304. Unique response pathways are established by allosteric interactions among nuclear hormone receptors
305. Regulation of human mesothelial cell differentiation: Opposing roles of retinoids and epidermal growth factor in the expression of intermediate filament proteins
306. Ligand-activated thyroid hormone and retinoic acid receptors inhibit growth factor receptor promoter expression
307. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation
308. Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism
309. E2F inhibits transcriptional activation by the retinoic acid receptor
310. Antagonism between retinoic acid receptors and AP-1: Implications for tumor promotion and inflammation
311. Hormone action II: Transcriptional regulation of endocrine genes by second messenger signalling pathways
312. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation
313. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
314. Nuclear receptor coactivators
315. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids
316. Synthesis and induction of tyrosine aminotransferase in synchronized hepatoma cells in culture
317. Cell cycle regulation of glucocorticoid receptor function
318. Regulation of epidermal growth factor receptors by glucocorticoids during the cell cycle in HeLa S3 cells
319. Identification of modified forms of human glucocorticoid receptors during the cell cycle
320. Agonist dependent phosphorylation and nuclear dephosphorylation of glucocorticoid receptors in intact cells
321. Cell cycle-dependent glucocorticoid receptor phosphorylation and activity
322. Site directed mutagenesis of the phosphorylation sites of the mouse glucocorticoid receptor
323. Role of acidic and phosphorylated residues in gene activation by the glucocorticoid receptor
324. Kinetics of glucocorticoid receptor phosphorylation in intact cells. Evidence for hormone-induced hyperphosphorylation after activation and recycling of hyperphosphorylated receptors
325. Inhibition of fibroblast proliferation and regulation of the cyclin kinase inhibitor p21(Cip1)
326. Involvement of the cell cycle inhibitor CIP1/WAF1 in lung alveolar epithelial cell growth arrest induced by glucocorticoids
327. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms
328. Role of transcriptional activation of IkBcα in mediation of immunosuppression by glucocorticoids
329. Immunosuppression by glucocorticoids: Inhibition of NF-kB activity through induction of IkB synthesis
330. Structure-function relationships in the vitamin D endocrine system
331. 3 metabolites
332. Effect of 1,25-dihydroxyvitamin D3 on mouse mammary tumor (GR) cells. Evidence for receptors, cellular uptake, inhibition of growth and alteration in morphology at physiologic concentrations of hormone
333. 20-Epivitamin D3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines
334. Antitumor effect of 22-oxa-1α,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene
335. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro
336. 3 Modulation of mammary tumor cell growth in vitro and in vivo
337. Vitamin D, calcium and epidermal differentiation
338. 3 with an oxygen atom in their side chain
339. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines
340. Novel regulatory action of 1,25-dihydroxyvitamin D on the metabolism of polyphosphoinositides in murine epidermal keratinocytes
341. 1,25 Dihydroxyvitamin D3 enhances antiproliferative effect and transcription of TGF-β1 on human keratinocytes in culture
342. 3 is linked to dephosphorylation of retinoblastoma gene product
343. Coupled down regulation of the RB retinoblastoma and c-myc genes antecede cell differentiation: Possible role of RB as a status quo gene
344. Inhibition of c-fos expression by an anti-sense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation
345. 3
346. 1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells
347. Induction of differentiation in human promyleocytic HL-60 leukemia cells activates, p21, WAF1/CIP1, expression in the absence of p53
348. p53-Independent induction of WAF/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation
349. Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells
350. Translational control of p27(Kip1) accumulation during the cell cycle
351. 3 leads to the induced differentiation of the myelomonocytic cell line U937
352. Overexpression of cyclin D1 in the Dami megakaryocytic cell line causes growth arrest
353. Hormonal effects on cell proliferation in rat prostate
354. Activation of programmed cell death in the rat ventral prostate after castration
355. Gene activity during the early phase of androgen-stimulated rat prostate regrowth
356. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction
357. Expression of the G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats
358. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of Cdk2, Cdk4 and CKIp16 genes
359. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
360. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
361. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
362. Regulating adipogenesis. Minireview
363. A novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation
364. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
365. The role of cyclic AMP in cell proliferation: A critical assessment of the evidence
366. The cyclic AMP-mediated stimulation of cell proliferation
367. Requirement for cAMP-PKA pathway activation by M phase promoting factor in the transition from mitosis to interphase
368. Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncoprotein
369. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant
370. Inhibition of signalling pathways for macrophage proliferation by cyclic AMP
371. Differential regulation of cell-cycle machinary by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints
372. Suppression of growth factor-induced CYL1 cyclin gene expression by antiproliferative agents
373. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor of cyclin-dependent kinase 4 activation
374. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts
375. Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM
376. The ATF site mediates downregulation of the cyclin A gene during contact inhibition in vascular endothelial cells
377. TGF-β1 and cAMP attenuate cyclin A gene transcription via a cAMP responsive element through independent pathways
378. Ectopic ICER expression in pituitary corticotroph AtT20 cells: Effect on morphology, cell cycle and hormonal regulation
379. 20S Cyclosome complex formation and proteolytic activity inhibited by the cAMP/PKA pathway
380. The regulation of transcription by phosphorylation
381. The study of tumor promotion in a cell culture model for mouse skin - A tissue that exhibits multistage carcinogenesis in vivo
382. Biological response to phorbol ester determined by alternative G1 pathways
383. AP2 inhibits cancer cell growth and activates p21(WAF/CIP1) expression
384. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements
385. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27
386. High frequency of aberrant p16(INK4A) expression in human breast cancer
387. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism
388. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study
389. Aberrant p27 kip1 expression in endocrine and other tumors
390. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas
391. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma
392. Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors?
393. Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice
394. Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene
395. Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues
396. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas
397. A frequent mutation/polymorphism in tumor suppressor gene INK4b (MTS-2) in papillary and medullary thyroid cancer
398. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas
399. Transforming growth factor-β, transforming growth factor-β receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries
400. Effects of an Rb mutation in the mouse
401. Heterozygous Rb-1 delta 20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance
402. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(±) mice
403. The retinoblastoma gene in human pituitary tumors
404. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus
405. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB
406. p53 Gene mutations in pituitary adenomas: Rare events
407. Cdk inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis
408. The cytogenesis and pathogenesis of pituitary adenomas
409. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome
410. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells
411. p16 Overexpression: A potential early indicator of transformation in ovarian carcinoma
412. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies
413. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium
414. Tumor induction and tissue atrophy in mice lacking E2F-1
415. E2F-1 functions in mice to promote apoptosis and suppress proliferation
416. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis
417. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation
418. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene
419. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma
420. Chromosome 11q13 abnormalities in human cancer
421. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression
422. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis
423. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
424. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value
425. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis
426. Function of human cyclin gene as an oncogene
427. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
428. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene
429. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice
430. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach
431. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia
432. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells
433. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
434. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells
435. Rac regulation of transformation, gene expression and actin organisation by multiple, PAK-independent pathways
436. Induction of cyclin D1 by simian virus 40 small tumor antigen
437. Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun
438. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels
439. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E
440. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse mariner
441. Overexpression of cyclin D1 enhances gene amplification
442. Chemical inhibitors of cyclin-dependent kinases
443. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2
444. Structure and cell cycle-regulated transcription of the human cyclin A gene
445. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein
446. Yeast TAF(II)145 required for transcription of G1/S cyclin genes and regulated by the cellular growth state
447. The human CCG1 gene, essential for progression of the G1 phase, encodes a 210-kilodalton nuclear DNA-binding protein
448. TAF(II)250-dependent transcription of cyclin A is directed by ATF activator proteins
449. Catalytic activation of extracellular signal-regulated kinases regulates cyclin D1 expression in primary tracheal myocytes
450. Inducible regulatory elements in the human Cyclin D1 promoter
451. pp60(v-src) Induction of cyclin D1 requires collaborative interactions between the ERK, p38 and Jun kinase pathways: A role for CREB and ATF-2 in pp60(v-src) signaling in breast cancer cells
452. Identification of the cyclin D1 gene as a target of ATF-2 in chondrocytes
453. Fos family members induce cell cycle entry by activating cyclin D1
454. The cyclin D-1 gene is a target of the β-catenin/LEF-1 pathway
455. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
456. Transcriptional regulation of cyclin D1 promoter by STAT5: Its involvement in cytokine-dependent growth of hematopoietic cells
457. Inhibition of cyclin D-kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1
458. 1 cyclin-Cdk complexes
459. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle
460. Cyclin D1 expression is regulated by the retinoblastoma protein
461. Differential modulation of cyclin gene expression by MYC
462. p53, Through p21 (WAF1/CIP1), induces cyclin D1 synthesis
463. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts
464. Functional analysis of the human cyclin D2 and cyclin D3 promoters
465. Structure and characterization of rat cyclin D3 promoter
466. Characterization of the mouse cyclin D3 gene: Exon/intron organization and promoter activity
467. Down-regulation of the cyclin A promoter by transforming growth factor-β1 is associated with a reduction in phosphorylated activating transcription factor-1 and cyclic AMP-responsive element-binding protein
468. Retinoblastoma protein recruits histone deacetylase to repress transcription
469. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
470. Cleavage of p21(Cip1/Waf1) and p27(Kip1) mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade
471. Activation of cyclin-dependent kinase-4 (Cdk4) by mouse MO15 associated kinase
472. Tumor suppressor p16(Ink44a): Determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4
473. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-Cdk complexes
474. Cell cycle regulation of cyclin A gene promoter is mediated by a variant E2F site
475. Cell cycle regulation of E2F site occupation in vivo
476. Cyclin A expression is under negative transcriptional control during the cell cycle
477. Stat3 as an oncogene
478. NF-KB controls cell growth and differentiation through transcriptional regulation of cyclin D1